Arbutus and Vaccitech Dose First Patient in Phase IIa Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Arbutus Biopharma Corporation and Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, announced the first patient dosed in a Phase IIa clinical trial for the treatment of patients with virologically-suppressed chronic Hepatitis B virus infection.